Overview

An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions when initiating or switching to insulin therapy with NovoMix® 30 in subjects with type 2 diabetes under normal clinical practice conditions
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Biphasic Insulins
Insulin
Insulin Aspart
Insulin aspart, insulin aspart protamine drug combination 30:70
Insulin, Isophane